CASI Pharmaceuticals Stock Forecast, Price & News

CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

Is CASI Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI Pharmaceuticals stock.
View analyst ratings for CASI Pharmaceuticals or view top-rated stocks.

How has CASI Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CASI shares have decreased by 46.9% and is now trading at $0.8650.
View which stocks have been most impacted by COVID-19.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for CASI Pharmaceuticals.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its quarterly earnings data on Friday, November, 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The biotechnology company had revenue of $8.11 million for the quarter, compared to analyst estimates of $7.77 million. CASI Pharmaceuticals had a negative net margin of 175.18% and a negative trailing twelve-month return on equity of 49.87%. During the same quarter in the prior year, the company posted ($0.14) earnings per share.
View CASI Pharmaceuticals' earnings history.

What guidance has CASI Pharmaceuticals issued on next quarter's earnings?

CASI Pharmaceuticals issued an update on its FY 2021 earnings guidance on Friday, November, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27.25 M-, compared to the consensus revenue estimate of $28.58 million.

What price target have analysts set for CASI?

3 analysts have issued 12-month target prices for CASI Pharmaceuticals' shares. Their forecasts range from $3.80 to $4.00. On average, they anticipate CASI Pharmaceuticals' share price to reach $3.93 in the next year. This suggests a possible upside of 354.7% from the stock's current price.
View analysts' price targets for CASI Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the following people:

• Wei-Wu He, Executive Chairman & Chief Executive Officer (LinkedIn Profile)
• Wei Zhang, President
• Alexander A. Zukiwski, Chief Medical Officer
• James E. Goldschmidt, Senior Vice President-Business Development

Who are some of CASI Pharmaceuticals' key competitors?

Some companies that are related to CASI Pharmaceuticals include Ikena Oncology (IKNA), Taysha Gene Therapies (TSHA), Aerie Pharmaceuticals (AERI), Athira Pharma (ATHA), Autolus Therapeutics (AUTL), Molecular Partners (MOLN), Curis (CRIS), Poseida Therapeutics (PSTX), Cortexyme (CRTX), CEL-SCI (CVM), Innate Pharma (IPHA), Cellectis (CLLS), Passage Bio (PASG), Innate Pharma (IPHYF) and Jounce Therapeutics (JNCE).
View all of CASI's competitors.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.16%), BlackRock Inc. (0.83%), Marshall Wace LLP (0.68%), Geode Capital Management LLC (0.68%), Millennium Management LLC (0.58%) and Cubist Systematic Strategies LLC (0.16%). Company insiders that own CASI Pharmaceuticals stock include Larry Zhang, Weihao Xu and Wei-Wu He.
View institutional ownership trends for CASI Pharmaceuticals.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, and BlackRock Inc..
View insider buying and selling activity for CASI Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Geode Capital Management LLC, Cubist Systematic Strategies LLC, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Goldman Sachs Group Inc., Citadel Advisors LLC, and UBS Group AG. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Larry Zhang, Weihao Xu, and Wei-Wu He.
View insider buying and selling activity for CASI Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $0.87.

How much money does CASI Pharmaceuticals make?

CASI Pharmaceuticals has a market capitalization of $120.92 million and generates $15.14 million in revenue each year. The biotechnology company earns $-48.29 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does CASI Pharmaceuticals have?

CASI Pharmaceuticals employs 144 workers across the globe.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com.

Where are CASI Pharmaceuticals' headquarters?

CASI Pharmaceuticals is headquartered at 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 864-2600, via email at [email protected], or via fax at 301-315-2437.